NR-LU-10 antibody

used for pretargeting metastatic colon cancer

Also Known As:

antibody NR-LU-10

Networked: 12 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        NR-LU-10 antibody: 12
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        NR-LU-10 antibody: 12
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        NR-LU-10 antibody: 12

Experts

1.	Weiden, P L: 2 articles (10/2001 - 02/2000)
2.	Axworthy, D: 2 articles (04/2001 - 02/2000)
3.	Breitz, H B: 1 article (10/2001)
4.	Goshorn, S: 1 article (04/2001)
5.	Hylarides, M: 1 article (04/2001)
6.	Lin, Y: 1 article (04/2001)
7.	Sanderson, J: 1 article (04/2001)
8.	Schultz, J: 1 article (04/2001)
9.	Adams, G P: 1 article (02/2000)
10.	Breitz, H: 1 article (02/2000)

Related Diseases

1.	Colonic Neoplasms (Colon Cancer) 01/01/1992 - "In order to confirm these predictions experimentally, this study compared the relative efficacy of a pancarcinoma antibody, NR-LU-10 labeled with 186Re or 131I in 0.8-1.0 mm diameter LS174T human colon adenocarcinoma multicell spheroids. " 02/01/2000 - "Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer."
2.	Lung Neoplasms (Lung Cancer) 08/01/1993 - "In 21 patients who had surgical correlation of mediastinal nodal involvement, NR-LU-10 was false-positive in 5 and false-negative in 1; results of computed tomography were false-positive in 6 and false-negative in 1. In this preliminary study, NR-LU-10 antibody scanning was safe and easily performed, it produced high-quality images of the lung and mediastinum, and it was accurate in detecting primary non-small-cell lung cancers. " 09/01/1997 - "Tc-99m nofetumomab merpentan (Verluma), consisting of a Fab fragment of the pancarcinoma murine antibody NR-LU-10, has been previously evaluated as a diagnostic imaging agent in staging patients with lung cancer. "
3.	Adenocarcinoma 10/01/2001 - "Pretargeted radioimmunotherapy (PRIT) was first investigated in a series of phase I and phase II studies in patients with adenocarcinoma using a pancarcinoma antibody, NR-LU-10. "
4.	Neoplasms (Cancer) 06/01/1993 - "We have estimated absorbed dose to normal organs and tumors following administration of two different 186Re-labeled immunoconjugates, intact NR-LU-10 antibody and the F(ab')2 fragment of NR-CO-02. " 04/01/2001 - "Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy." 01/01/1998 - "Subsequent reaction with NR-LU-10 antibody Fab fragment followed by purification via QAE Sephadex anion exchange resin filter afforded 99mTc-N3S-NR-LU-10 Fab conjugate with retained immunoreactivity and effective tumor targeting properties."
5.	Ovarian Neoplasms (Ovarian Cancer) 12/01/1995 - "administration of a 186Re-labeled murine antibody, NR-LU-10, in 27 patients with advanced ovarian cancer. " 05/01/1995 - "Pharmacokinetics, biodistribution and radiation dose estimates following intraperitoneal administration of a 186Re-labeled murine antibody, NR-LU-10, were assessed in 27 patients with advanced ovarian cancer. "

Related Drugs and Biologics

1.	Streptavidin
2.	DOTA-biotin (90Y-DOTA-biotin)
3.	procaine isothiocyanate (PRIT)
4.	Immunoglobulin Fab Fragments
5.	Immunoconjugates (Immunoconjugate)
6.	Proteins (Proteins, Gene)
7.	Immunotoxins (Immunotoxin)
8.	Anion Exchange Resins
9.	technetium Tc 99m-nofetumomab merpentan (Verluma)
10.	sephadex

Related Therapies and Procedures

1.	Radioimmunotherapy
2.	Therapeutics